Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

nichi-iko pharmaceutical co.,ltd - amikacin sulfate - injection

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

nichi-iko pharmaceutical co.,ltd - amikacin sulfate - injection

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

nichi-iko pharmaceutical co.,ltd - amikacin sulfate - injection

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

nichi-iko pharmaceutical co.,ltd - amikacin sulfate - injection

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - amikacin sulfate, quantity: 1336 mg (equivalent: amikacin, qty 1000 mg) - solution - excipient ingredients: sodium chloride; sodium hydroxide; water for injections; hydrochloric acid - amikacin kabi is indicated in the short-term treatment of serious infections caused by susceptible strains of gram-negative bacteria, (see section 5.1 pharmacodynamic properties). staphylococcus aureus, including methicillin-resistant strains is the principal gram-positive organism sensitive to amikacin. the use of amikacin in the treatment of staphylococcal infections should be restricted to second-line therapy, and should be confined to patients suffering from severe infections caused by susceptible strains of stapylococcus who have failed to respond or are allergic to other available antibiotics. amikacin kabi is indicated in the treatment of neonatal sepsis when sensitivity testing indicates that other aminoglycosides cannot be used. in certain severe infections such as neonatal sepsis, concomitant therapy with a penicillin type drug may be indicated because of the possibility of infections due to gram-positive organisms such as streptococci or pneumococci. if concomitant treatment with a penicillin type drug is indicated, then the drugs should be administered separately because in-vitro mixing of the two drugs causes inactivation of amikacin. clinical studies have shown amikacin to be effective in treating bacteraemia, septicaemia including neonatal sepsis and serious infections of the respiratory tract, bones and joints, central nervous system, skin and skin structures (including those resulting from burns), intra-abdominal organs, post-operative infections and complicated and recurrent urinary tract infections, when caused by susceptible organisms.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - amikacin sulfate, quantity: 334 mg (equivalent: amikacin, qty 250 mg) - solution - excipient ingredients: sodium chloride; sodium hydroxide; water for injections; hydrochloric acid - amikacin kabi is indicated in the short-term treatment of serious infections caused by susceptible strains of gram-negative bacteria, (see section 5.1 pharmacodynamic properties). staphylococcus aureus, including methicillin-resistant strains is the principal gram-positive organism sensitive to amikacin. the use of amikacin in the treatment of staphylococcal infections should be restricted to second-line therapy, and should be confined to patients suffering from severe infections caused by susceptible strains of stapylococcus who have failed to respond or are allergic to other available antibiotics. amikacin kabi is indicated in the treatment of neonatal sepsis when sensitivity testing indicates that other aminoglycosides cannot be used. in certain severe infections such as neonatal sepsis, concomitant therapy with a penicillin type drug may be indicated because of the possibility of infections due to gram-positive organisms such as streptococci or pneumococci. if concomitant treatment with a penicillin type drug is indicated, then the drugs should be administered separately because in-vitro mixing of the two drugs causes inactivation of amikacin. clinical studies have shown amikacin to be effective in treating bacteraemia, septicaemia including neonatal sepsis and serious infections of the respiratory tract, bones and joints, central nervous system, skin and skin structures (including those resulting from burns), intra-abdominal organs, post-operative infections and complicated and recurrent urinary tract infections, when caused by susceptible organisms.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - amikacin sulfate, quantity: 668 mg (equivalent: amikacin, qty 500 mg) - solution - excipient ingredients: sodium chloride; sodium hydroxide; water for injections; hydrochloric acid - amikacin kabi is indicated in the short-term treatment of serious infections caused by susceptible strains of gram-negative bacteria, (see section 5.1 pharmacodynamic properties). staphylococcus aureus, including methicillin-resistant strains is the principal gram-positive organism sensitive to amikacin. the use of amikacin in the treatment of staphylococcal infections should be restricted to second-line therapy, and should be confined to patients suffering from severe infections caused by susceptible strains of stapylococcus who have failed to respond or are allergic to other available antibiotics. amikacin kabi is indicated in the treatment of neonatal sepsis when sensitivity testing indicates that other aminoglycosides cannot be used. in certain severe infections such as neonatal sepsis, concomitant therapy with a penicillin type drug may be indicated because of the possibility of infections due to gram-positive organisms such as streptococci or pneumococci. if concomitant treatment with a penicillin type drug is indicated, then the drugs should be administered separately because in-vitro mixing of the two drugs causes inactivation of amikacin. clinical studies have shown amikacin to be effective in treating bacteraemia, septicaemia including neonatal sepsis and serious infections of the respiratory tract, bones and joints, central nervous system, skin and skin structures (including those resulting from burns), intra-abdominal organs, post-operative infections and complicated and recurrent urinary tract infections, when caused by susceptible organisms.

Australia - English - Department of Health (Therapeutic Goods Administration)

medsurge pharma pty ltd - amikacin sulfate, quantity: 667.6 mg (equivalent: amikacin, qty 500 mg) - injection, solution - excipient ingredients: water for injections; sodium metabisulfite; sodium citrate dihydrate; sulfuric acid - amikacin injection is indicated in the short-term treatment of serious infections caused by susceptible strains of gram-negative bacteria, (see section 5.1 pharmacodynamic properties).,staphylococcus aureus, including methicillin-resistant strains is the principal gram-positive organism sensitive to amikacin.,the use of amikacin in the treatment of staphylococcal infections should be restricted to second-line therapy, and should be confined to patients suffering from severe infections caused by susceptible strains of staphylococcus who have failed to respond or are allergic to other available antibiotics.,amikacin injection is indicated in the treatment of neonatal sepsis when sensitivity testing indicates that other aminoglycosides cannot be used.,in certain severe infections such as neonatal sepsis, concomitant therapy with a penicillin type drug may be indicated because of the possibility of infections due to gram-positive organisms such as streptococci or pneumococci. if concomitant treatment with a penicillin type drug is indicated, then the drugs should be administered separately because in-vitro mixing of the two drugs causes inactivation of amikacin.,clinical studies have shown amikacin to be effective in treating bacteraemia, septicaemia including neonatal sepsis and serious infections of the respiratory tract, bones and joints, central nervous system, skin and skin structures (including those resulting from burns), intra- abdominal organs, post-operative infections and complicated and recurrent urinary tract infections, when caused by susceptible organisms.

Australia - English - Department of Health (Therapeutic Goods Administration)

medsurge pharma pty ltd - amikacin sulfate, quantity: 667.6 mg (equivalent: amikacin, qty 500 mg) - injection, solution - excipient ingredients: sulfuric acid; sodium citrate dihydrate; sodium metabisulfite; water for injections - amikacin injection is indicated in the short-term treatment of serious infections caused by susceptible strains of gram-negative bacteria, (see section 5.1 pharmacodynamic properties).,staphylococcus aureus, including methicillin-resistant strains is the principal gram-positive organism sensitive to amikacin.,the use of amikacin in the treatment of staphylococcal infections should be restricted to second-line therapy, and should be confined to patients suffering from severe infections caused by susceptible strains of staphylococcus who have failed to respond or are allergic to other available antibiotics.,amikacin injection is indicated in the treatment of neonatal sepsis when sensitivity testing indicates that other aminoglycosides cannot be used.,in certain severe infections such as neonatal sepsis, concomitant therapy with a penicillin type drug may be indicated because of the possibility of infections due to gram-positive organisms such as streptococci or pneumococci. if concomitant treatment with a penicillin type drug is indicated, then the drugs should be administered separately because in-vitro mixing of the two drugs causes inactivation of amikacin.,clinical studies have shown amikacin to be effective in treating bacteraemia, septicaemia including neonatal sepsis and serious infections of the respiratory tract, bones and joints, central nervous system, skin and skin structures (including those resulting from burns), intra- abdominal organs, post-operative infections and complicated and recurrent urinary tract infections, when caused by susceptible organisms.

Kenya - English - Pharmacy and Poisons Board

ms pharma- jordan king abdullah (ii) bin al-hussein industrial - amikacine sulphate ep equivalent to amikacin - solution for injection - each 2ml vial contains amikacine sulphate ep… - amikacin